News About: Pharm. Affairs
Adcetris, an ADC, receives the health insurance benefit exempted from total amount limit
An antibody-drug conjugate(ADC) has overcame the wall of the health insurance benefit. It also did not get restricted by the total amount limit of the economic evaluation exception.
The Health Insurance Review & Asse...
Boehringer’s approved ‘Jardiance Duo’ fuels competition among SGLT-2 complexesIn the SGLT-2-inhibitor antidiabetic treatment market led by AstraZeneca’s ‘Forxiga(dapagliflozin)’ by itself, competition is expected among complexes.
According to the industr...
|
Asia-Pacific countries including Korea are expected to enlarge generic shares
It was diagnosed the proportion of generic products is increasing in most Asia-Pacific regions and the trend will continue in the future.
According to the ‘Patent Cliff and Asian Generic Products’ Present and Future ...
Harvoni registers its name in the pharmaceutical patent list
Harvoni Tab(sofosbuvir, ledipasvir), a hepatitis C treatment, register its name in the pharmaceutical patent list.
In the Ministry of Food and Drug Safety’s ‘Pharmaceutical Patent List,’ Gilead Sciences Korea was kno...
Creations of health insurance benefits for NOAC Lixiana
While the use of novel oral anticoagulants(NOAC) has steadily increased, ‘Lixiana’ is expected to be applied by the health insurance benefit.
On the 19th, the Ministry of Health and Welfare announced it will establis...
Sovaldi and Harvoni land on 13 hospitals and start to be supplied
Prescriptions of ‘Sovaldi(sofosbuvir),’ a large hepatitis C treatment, and ‘Harvoni(sofosbuvir and ledipasvir),’ a complex, have started in the domestic market.
Gilead Sciences Korea announced supply of the two oral ...
Continuous increase of convenient stores reporting the medical device business
The number of convenient stores, which would like to handle in vitro diagnostic agents, such as pregnancy test kits, was observed to increase gradually after the agents was transferred to medical devices.
Yongsan-gu ...
High interests in the Botox’s application of the insurance benefit as migraine treatmentWith declaration of the Headache Day, the insurance benefit of ‘Botox’ has attracted interests of the industry as a chronic migraine treatment. Application of the benefit is exp...
|
Like the patent expiration of erectile dysfunction, will expired ‘Avodart’ lead changes?
Since the substance patent of GSK’s ‘Avodart(dutasteride),’ used as a hair loss and prostatism treatment, was expired today(21st), domestic pharmaceutical companies, such as Kukje Pharm, KyungDong Pharm, Kwang Dong Ph...
Will multiple myeloma treatment meet a new paradigm?
As a number of products emerges – DDP-4 inhibitors, SGLT-2 inhibitors, basal insulin and GLP-1 agonists –, ‘diabetes treatment’ has met a new treatment paradigm. Emergence of various treatments has allowed patients to...
